At the 2025 High-Quality Development Conference for Innovative Drugs held yesterday, the updated National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance, along with the inaugural Commercial Health Insurance Innovative Drug List (2025), was officially released. This marks the eighth adjustment to the NRDL since the establishment of the National Healthcare Security Administration, adding 114 new drugs, including six traditional Chinese medicine (TCM) products, further expanding patient access to medication.
According to the disclosed list, the six newly added TCMs are: Wenyang Jiedu Granules, Shenyu Ningshen Tablets, Yangxue Qufeng Zhitong Granules, Yiqi Qingfei Granules, Yunüjian Granules, and Qifang Bitong Tablets. Among them, three are classified as 1.1-class new drugs, and three as 3-class new drugs. Notably, all these drugs were recently approved, having obtained their Drug Registration Certificates within the past two years.
Qifang Bitong Tablets, developed by Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ), was approved in January 2025. According to the company’s announcement, this 1.1-class new drug, produced by its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co., Ltd., is an exclusive product for treating persistent allergic rhinitis.
Yangxue Qufeng Zhitong Granules, developed by Hunan Fangsheng Pharmaceutical Co., Ltd.’s (603998.SH) subsidiary Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., is indicated for frequent tension-type headaches classified under TCM syndrome patterns of qi and blood deficiency.
Shenyu Ningshen Tablets, owned by Yili Pharmaceutical (Luoding) Co., Ltd., is designed to replenish qi, nourish yin, and calm the mind, targeting mild to moderate depression with qi-yin deficiency syndrome.
Among the 3-class TCMs, Yunüjian Granules, listed in the Ancient Classical Prescriptions Catalog, is currently an exclusive product of Jiangsu Kanion Pharmaceutical Co., Ltd. (600557.SH). The company is advancing clinical efficacy evaluations and mechanism studies for its application in type 2 diabetes with excessive heat and yin deficiency. Additionally, Kanion’s 3.2-class new drug, Wenyang Jiedu Granules, also made it into the NRDL. This formulation originated from the "Fuzheng Jiedu Formula," a TCM prescription developed by Guangdong Provincial Hospital of Traditional Chinese Medicine’s medical team during the 2020 pandemic, targeting patients with yang qi deficiency and pathogenic toxin invasion.
Yiqi Qingfei Granules, under China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ), is the company’s first approved 3.2-class TCM. The prescription, named "Qingjin Yiqi Formula," was developed by academician Zhang Boli in 2020 for treating post-respiratory infection recovery symptoms.
The updated NRDL now includes 3,253 drugs, with 1,396 being TCMs, and will take effect on January 1, 2026. The introduction of the Commercial Health Insurance Innovative Drug List (2025) aims to enhance the multi-tiered healthcare security system, providing patients with more comprehensive medication support.
Comments